Yin-Ku Lin,1,2 Ching-Ya Wang,3,4 Yu-Huei Huang,3,4 Ya-Ching Chang,3,4 Chun-Bing Chen,3– 9 Chuang-Wei Wang,3,5– 7,* Rosaline Chung-Yee Hui,3,4,* Wen-Hung Chung3,5– 12,*
1Division of Conventional Chinese language Drugs, Chang Gung Memorial Hospital, Keelung, Taiwan; 2Faculty of Conventional Chinese language Drugs, Faculty of Drugs, Chang Gung College, Taoyuan, Taiwan; 3Chang Gung Memorial Hospital, Linkou Department, Taoyuan, Taiwan; 4Faculty of Drugs, Chang Gung College, Taoyuan, Taiwan; 5Most cancers Vaccine and Immune Cell Remedy Core Laboratory, Chang Gung Memorial Hospital, Linkou, Taiwan; 6Chang Gung Immunology Consortium, Chang Gung Memorial Hospital and Chang Gung College, Linkou, Taiwan; 7Division of Dermatology, Xiamen Chang Gung Hospital, Xiamen, Individuals’s Republic of China; 8Entire-Genome Analysis Core Laboratory of Human Ailments, Chang Gung Memorial Hospital, Keelung, Taiwan; 9Immune-Oncology Middle of Excellence, Chang Gung Memorial Hospital, Linkou, Taiwan; 10Division of Dermatology, Beijing Tsinghua Chang Gung Hospital, Faculty of Scientific Drugs, Tsinghua College, Beijing, Individuals’s Republic of China; 11Faculty of Drugs, Shanghai Jiao Tong College, Shanghai, Individuals’s Republic of China; 12Genomic Drugs Core Laboratory, Chang Gung Memorial Hospital, Linkou, Taiwan
Correspondence: Wen-Hung Chung, Chang Gung Memorial Hospital, Linkou Department, No. 5, Fusing St, Taoyuan, 333, Taiwan, Tel +886 3-3281200 #8495, Fax +886 3-3281200 #2206, E-mail [email protected]; [email protected]
Goal: Lindioil, a medication refined from indigo naturalis (a herb utilized in Chinese language medication), is efficient in treating extreme psoriasis; nonetheless, responses differ throughout particular person sufferers. We purpose to analyze genetic predispositions related to remedy response to topical Lindioil amongst sufferers with psoriasis and correlations with plasma cytokine patterns.
Sufferers and Strategies: We enrolled 72 psoriasis sufferers handled with Lindioil ointment and analyzed the human leukocyte antigen class C (HLA-Cw) genotypes and plasma cytokine expression patterns. We developed regression fashions of remedy response, outlined as Psoriasis Space and Severity Index (PASI) 75, to look at correlations amongst HLA-Cw alleles, cytokine ranges, and remedy response to Lindioil.
Outcomes: Sufferers harboring HLA-Cw*06:02 have been considerably extra possible to reply to Lindioil (P = 0.02, odds ratio [OR]: 6.88), whereas Lindoil was ineffective in these harboring HLA-Cw*01:02 (P = 0.01, OR: 0.28). Sufferers who have been HLA-Cw*06:02-positive or HLA-Cw*01:02-negative had higher PASI scores and physique floor space (BSA) enchancment (73.3% vs 44.4%, PP = 0.05).
Conclusion: Our findings counsel that the presence of the HLA-Cw*06:02 or HLA-Cw*01:02 alleles and plasma IL-17 ranges are predictive markers of remedy response to Lindioil ointment in sufferers with psoriasis.
Key phrases: HLA-Cw*06:02, HLA-Cw*01:02, indigo naturalis, Lindioil, IL-17, psoriasis
Introduction
Psoriasis is a standard, continual, immune-mediated, inflammatory pores and skin illness. Psoriasis outcomes from an aberrant innate or adaptive immune response related to T lymphocytes that results in epidermal hyperplasia1 and is characterised by salmon-pink plaques with heavy silver scales.2 Psoriasis has damaging results on the affected person’s well being and high quality of life, together with psychosocial and financial impacts.3,4 The illness pathogenesis represents a posh interaction amongst genetic, environmental, and immunological elements. Sure alleles encoding human leukocyte antigen-Cw (HLA-Cw), similar to HLA-Cw*06:02, have been recognized as essential genetic determinants of psoriasis growth.5 HLA-Cw gene expression has been linked to psoriasis incidence, severity, phenotypic options, and remedy outcomes.6 The presence of HLA-Cw*06:02 has been instructed to function a predictive marker for the scientific response to ustekinumab (IL-12/23 antibody) and methotrexate remedy in psoriasis.7,8 Numerous therapies with completely different targets have been developed to alleviate psoriasis signs, together with systemic remedy, phototherapy, topical remedy, and conventional Chinese language medication (TCM). The topical utility of ointments developed from indigo naturalis a generally used herb in TCM, has been proposed as a sexy remedy choice with decrease prices and diminished prevalence of long-term unintended effects in contrast with different anti-psoriasis remedies.9,10
Indigo naturalis is derived from a blue powder extracted from indigo vegetation, similar to Baphicacanthus cusia.11 Indigo naturalis has been broadly utilized in TCM for the remedy of inflammatory illnesses and dermatosis for hundreds of years.12 Indigo naturalis has been demonstrated to have anti-inflammatory and anti-proliferative properties by way of a number of mechanisms, mediated by its lively elements, together with indirubin, indigo, and tryptanthrin.13 Indirubin, the essential main lively part, inhibits the proliferation of epidermal keratinocytes by way of the inhibition of cyclin-dependent kinase14,15 and epidermal development issue receptor (EGFR) activation.16,17 As well as, indirubin suppresses pores and skin irritation by inhibiting cytokine manufacturing, nuclear issue kappa B (NF-κB) exercise, and mitogen-activated protein kinase signaling.18,19 Tryptanthrin additionally possesses anti-inflammatory properties that attenuate the T-helper 17 (Th17) signature12 and downregulate the IL-17 pathway.20 One other part, indigo, is much less lively than the opposite two,10 however each indigo and indirubin activate the aryl hydrocarbon receptor signaling pathway to modulate the immune response.21,22 Indigo naturalis in its crude kind has additionally been proven to cut back T cell adhesion by suppressing tumor necrosis issue (TNF)-α–induced expression of vascular cell adhesion molecule 1 (VCAM-1).23
Lindioil is a refined type of indigo naturalis ointment powder, with the unique blue coloration eliminated to forestall staining (staining of pores and skin and garments was the rationale for poor affected person compliance with crude indigo naturalis ointment); Lindoil stays a secure and efficient remedy.10 Our Scientific trial11 confirmed that 200 µg/g of indirubin in Lindioil ointment was the best focus for topical psoriasis remedy. Nevertheless, remedy response diverse throughout particular person sufferers, and the underlying mechanisms that result in differential responses stay unclear. Though the HLA-Cw allele and the IL-17/IL-23 mediated pathway are thought to be essential elements within the response to psoriasis remedy, the associations amongst HLA allele standing, plasma cytokine ranges, and response to Lindioil remedy haven’t but been completely explored. Subsequently, to enhance our means to offer exact and efficient remedy choices, we tried to determine helpful biomarkers for predicting the remedy response to Lindioil ointment amongst psoriasis sufferers.
Supplies and Strategies
Examine Inhabitants
Between November 2012 and April 2014, 72 sufferers have been recognized for examine inclusion who have been identified with plaque psoriasis for no less than 1 12 months, with <20% of their physique floor space (BSA) affected by psoriasis, and a Psoriasis Space and Severity Index (PASI) sCore <20. Washout intervals of no less than 4 weeks following the tip of systemic remedy or phototherapy regimens and no less than 2 weeks following the tip of topical therapies have been required previous to the initiation of examine treatment. All sufferers have been beforehand enrolled in our scientific trial examine, which is registered with ClinicalTrials.gov (identifier NCT01735864), and have been handled with Lindioil for no less than 8 weeks. After completion of the scientific trial, we used the remaining DNA and plasma samples from enrolled sufferers to carry out HLA-Cw genotyping and consider cytokine expression, respectively. All members supplied written knowledgeable consent and agreed to the usage of their samples for this examine (IRB No. 201507317B0). The examine was performed at Chang Gung Memorial Hospital, Linkou, and Taipei branches. The protocol was permitted by the institutional evaluation boards of Chang Gung Memorial Hospital in Taiwan. The examine was performed in accordance with the Declaration of Helsinki and Good Scientific Practices.
Human Leukocyte Antigen Genotyping
All 72 sufferers have been genotyped for HLA-Cw alleles utilizing SeCore HLA sequence–based mostly typing (SBT) (Invitrogen, Life Applied sciences, Carlsbad, CA). The HLA-Cw genotyping information for 507 people within the common Chinese language inhabitants with no historical past of extreme pores and skin issues was obtained as described beforehand.24
Cytokine Stage Evaluation
The 64 sufferers with psoriasis have been analyzed for cytokine expression patterns, together with IL-6, IL-17, IL-22, IL-23, and TNF-α. The concentrations of those cytokines in plasma have been decided through the use of the Bio-Plex professional assays (Bio-Rad Laboratories, Irvine, California), in keeping with the producer’s directions. All samples have been analyzed in duplicate.
Definition of Remedy Response
PASI scores have been recorded at baseline and weeks 8, 12, and 20 following initiation of remedy. The imply proportion of PASI rating enchancment at weeks 8, 12, and 20 have been calculated, and the proportions of sufferers reaching no less than 50% discount (PASI 50), 75% discount (PASI 75), and 90% discount (PASI 90) at every time level have been in contrast between HLA genotypes. Constructive remedy response was outlined as no less than PASI 75 relative to baseline. Sufferers reaching PASI 75 have been thought-about good responders, whereas those that didn’t obtain PASI 75 have been labeled as poor responders. We evaluated the imply proportion of enchancment in PASI and BSA scores at weeks 8, 12, and 20.
Statistical Analyses
Statistical evaluation was carried out utilizing SPSS for Home windows software program model 21.0 (IBM Corp, Armonk, NY). Information are offered because the quantity (proportion) for categorical variables and because the imply ± normal deviation (SD) for steady variables. Variations have been evaluated utilizing Fisher’s actual check for categorical variables, whereas an impartial two-tailed t-test was used to judge variations in steady variables. Solely these variables with P<0.05 in univariate analyses have been included within the a number of regression evaluation for remedy response. A two-tailed P-value <0.05 was thought-about vital.
Outcomes
Table 1 exhibits the demographic and scientific traits of the 72 sufferers with psoriasis (together with 43 males and 29 ladies) handled with Lindioil included on this examine. The imply age of the sufferers was 35.3±8.2 years, and the imply physique mass index was 24.6±4.1 kg/m2. The imply period of psoriasis was 11.2±7.5 years, and all sufferers (100%) had obtained prior remedy, together with 2 sufferers handled with the biologic etanercept. As well as, 98.6% used topical remedy, and 76.4% of sufferers used Chinese language herbs in both oral or topical types. The imply PASI rating and BSA% affected by psoriasis at baseline have been 11.8±4.2 and 10.6%±6.0%, respectively. The imply period of Lindioil remedy was 17.0±5.6 weeks. After 8 weeks of remedy, 51.4% had achieved no less than PASI 50, and 47.2% of sufferers had achieved PASI 75. Nevertheless, 5 sufferers (6.9%) skilled treatment-related antagonistic occasions (AEs). Remedy-related AEs in our examine included acute psoriasis flare-ups, contact dermatitis, allergic exanthema, eczema, and pores and skin irritation.
Desk 1 Demographic and Scientific Traits of Enrolled Examine Inhabitants |
We first carried out SBT to find out the person HLA-Cw genotypes amongst our examine inhabitants (Supplementary Table S1) and located that the HLA-Cw*06:01 allele was considerably related to psoriasis in contrast with 507 wholesome controls with no historical past of extreme pores and skin issues (P=0.0008, Supplementary Table S2). Additional evaluation of the correlations between HLA-Cw standing and remedy response to Lindioil revealed that sufferers had poorer responses when carrying the HLA-Cw*01:02 allele (good responders vs poor responders carrying the HLA-Cw*01:02 allele, 29.4% vs 57.9%; odds ratio [OR]: 0.60, 95% confidence interval [CI], 0.39–0.92; P=0.019, Table 2), whereas these had higher responses when carrying the HLA-Cw*06:02 allele (good responders vs poor responders carrying the HLA-Cw*06:02 allele, 29.4% vs 7.9%; OR: 1.31; 95% CI: 1.03–1.65; P=0.03, Table 2). Within the multivariate evaluation, HLA-Cw*01:02 was related to the remedy response (OR: 0.35; 95% CI” 0.13–0.96; P=0.042, Supplementary Table S3). No vital variations of demographic, scientific options and antagonistic occasion have been noticed between the nice and poor responder teams (Table 2). To enhance the sensitivity to foretell the response to Lindioil remedy, we mixed these two related HLA-Cw alleles and located that 73.5% (25 in 34 sufferers) sufferers who achieved PASI 75 (good responders) at week 8 have been HLA-Cw*01:02-negative or HLA-Cw*06:02-positive (P=0.031, Table 2).
Desk 2 Demographic and Scientific Traits of Good and Poor Responders Handled with Lindioil Ointment |
We additional analyzed and in contrast these two HLA genes after 20 weeks of Lindioil remedy. Amongst our cohort (Table 3 and Figure 1A–C), 32 sufferers (44.4%) have been HLA-Cw*01:02-positive and 40 sufferers (55.6%) have been HLA-Cw*01:02-negative. The HLA-Cw*01:02-negative group had an extended psoriasis period than the HLA-Cw*01:02-positive group (imply 12.9 years vs 9.1 years, P=0.037). No different vital variations in scientific baseline parameters have been recognized between HLA-Cw*01:02 teams. The proportion of HLA-Cw*01:02-negative sufferers who achieved PASI 75 (good responders) was increased than that of HLA-Cw*01:02-positive sufferers (60.0% vs 31.3%, P=0.019) at week 8, and HLA-Cw*01:02-negative sufferers had higher PASI enhancements (rating enchancment 64.8% vs 46.3%, P=0.018) and BSA enhancements (55.2% vs 28.6%, P=0.036) after 8 weeks of Lindioil remedy. HLA-Cw*01:02-negative sufferers additionally confirmed considerably bigger enhancements in imply PASI and BSA after 12 (PASI: 67.8% vs 50.0%, P=0.018; BSA: 62.0% vs 33.6%, P=0.026) and 20 weeks of remedy (PASI: 70.4% vs 51.6%, P=0.017; BSA: 65.1% vs 38.1%, P=0.041).
Desk 3 Demographic and Scientific Traits of HLA-Cw*01:02 Constructive/Detrimental Sufferers Handled with Lindioil |
We then analyzed the HLA-Cw*06:02 allele (Table 4 and Figure 1D–F) and located that 13 sufferers (18.1%) have been HLA-Cw*06:02-positive, and 59 sufferers (81.9%) have been HLA-Cw*06:02-damaging. No vital variations have been recognized in any scientific baseline parameters between these two teams. The proportion of HLA-Cw*06:02-positive sufferers who achieved PASI 75 (good responders) was increased than the share of HLA-Cw*06:02-negative sufferers (76.9% vs 40.7%, P=0.029), and HLA-Cw*06:02-positive sufferers offered with bigger enhancements in PASI (74.6% vs 52.6%, P=0.005) and BSA (73.3% vs 36.8%, P<0.001) after 8 weeks of Lindioil remedy. As well as, we noticed that HLA-Cw*06:02-positive sufferers confirmed considerably bigger enhancements in imply PASI and BSA after 12 (PASI: 75.0% vs 56.5%, P=0.013; BSA: 79.3% vs 42.7%, P=0.001) and 20 weeks of remedy (PASI: 81.4% vs 57.8%, P=0.001; BSA: 84.9% vs 46.1%, P<0.001). Equally, HLA-Cw*06:02-positive sufferers achieved PASI 75 extra ceaselessly in any respect time factors, though no vital distinction was noticed between the 2 teams at week 20. We additionally analyzed the relationships between response outcomes, AEs, and HLA-Cw alleles and located no vital associations (Supplementary Table S4).
Desk 4 Demographic and Scientific Traits of HLA-Cw*06:02 Constructive/Detrimental Sufferers Handled with Lindioil |
The cytokine evaluation confirmed that sufferers who achieved PASI 75 after 8 weeks of remedy offered with decrease baseline plasma IL-17 expression ranges than those that didn’t obtain PASI 75 after 8 weeks (11.28 pg/mL vs 15.82 pg/mL, P=0.05, Figure 2), whereas no vital variations have been recognized in different baseline cytokine expression ranges, together with IL-6, IL-22, IL-23 and TNF-α (Supplementary Table S5). No vital variations in baseline cytokine ranges have been noticed between sufferers who did and didn’t obtain PASI 50 after 8 weeks of remedy.
Dialogue
The applying of predictive genetic markers to remedy choice may reveal whether or not a given remedy is prone to lead to response for the affected person. Psoriasis is a continual, long-term illness with a protracted common period, and the identification of simpler remedies is a excessive precedence for sufferers. HLA-Cw*06:02 has beforehand been recognized as a significant genetic susceptibility allele for psoriasis,24 and the findings of the current examine are in keeping with earlier genetic findings. Each methotrexate and ustekinumab have been proven to be simpler in HLA-Cw*06:02-positive sufferers,7,8,25 whereas no relationships have been recognized between HLA-Cw6 standing and remedy response to secukinumab,26 etanercept, or infliximab.27 One other biologic agent, adalimumab, was discovered to lead to a poorer response than ustekinumab in HLA-Cw*06:02-positive sufferers.28 Furthermore, fewer methotrexate treatment-related AEs have been reported amongst HLA-Cw*06:02-positive sufferers.7 HLA-Cw*01 ceaselessly seems amongst sufferers with psoriasis in a number of international locations, significantly Asian international locations, with a frequency starting from 2.4% to 27%.29–33 Cai and others highlighted that HLA-Cw*01:02 is a psoriasis-associated allele in Southern Han Chinese language. Furthermore, HLA-Cw*01:02-positive sufferers tended to point out no response to standard therapies.30,34 In our examine, 32 of 72 (44.4%) members have been HLA-Cw*01:02-positive, and all sufferers had obtained typical psoriasis remedy previous to our examine. The comparatively excessive HLA-Cw*01:02 frequency of our examine inhabitants might point out a bent for this inhabitants to expertise an total poor response to standard therapies, highlighting the necessity to develop various remedy methods. The identification of gene standing amongst sufferers with psoriasis can enhance customized medication approaches, stopping the waste of money and time on remedies which are unlikely to be efficient. Nevertheless, at the moment, no proof exists to assist a relationship between genetic elements and the remedy response to Lindioil, a fast-acting topical remedy for psoriasis sufferers. On this examine, we used the DNA database from our earlier scientific trial11 to investigate the correlation between HLA-Cw allele standing and the remedy response to Lindioil.
We recognized that HLA-Cw*06:02-positive and HLA-Cw*01:02-negative sufferers have been extra prone to be good responders to Lindioil remedy than sufferers with different allele displays. Our outcomes additional revealed that HLA-Cw*06:02-positive and HLA-Cw*01:02-negative sufferers confirmed higher responses to Lindioil remedy than sufferers with different allele displays throughout a number of response evaluations, together with imply PASI enchancment, the proportion of sufferers reaching PASI 75, and imply BSA enchancment. When analyzing scientific baseline parameters, HLA-Cw*01:02-negative sufferers have been discovered to have longer psoriasis historical past; nonetheless, no affiliation was reported between illness period and remedy response by Edson-Heredia and others.35 Amongst these with good responses to Lindioil remedy, 73.5% have been HLA-Cw*01:02-negative or HLA-Cw*06:02-positive, suggesting that each the HLA-Cw*01:02 and HLA-Cw*06:02 alleles take part within the pharmacological mechanism underlying the results of Lindioil. The discovering that HLA-Cw*01:02-positive sufferers confirmed a worse response to Lindioil than HLA-Cw*01:02-negative sufferers is in keeping with one alefacept response examine.30 Additional examine stays vital to find out the pathogenic mechanisms related to HLA-Cw*01:02 in psoriasis and the biogenetic mechanism that determines the response of sufferers with HLA-Cw*01:02 or HLA-Cw*06:02 alleles to Lindioil remedy.
The diminished incidence of treatment-related AEs is among the many benefits of topical Lindioil use. Among the many 6 sufferers who skilled Lindioil-related AEs, 2 have been HLA-Cw*01:02-negative, and only one was HLA-Cw*06:02-positive. None of those 6 sufferers have been each HLA-Cw*01:02-negative and HLA-Cw*06:02-positive. Though an inadequate variety of circumstances skilled AEs for statistical analyses, our findings instructed that HLA-Cw*06:02-positive and HLA-Cw*01:02-negative sufferers have been much less prone to undergo from treatment-related AEs than sufferers with different allelic mixtures. We additionally recognized that the IL-17 signaling pathway is concerned within the remedy response to Lindioil. Considerably decreased plasma ranges of IL-6, IL-17, IL-22, IL-23, and TNF-α have been noticed in good responders in contrast with poor responders. The first lively compounds in indigo naturalis have been reported to attenuate IL-17A expression, and our outcomes point out that topical remedy with Lindioil ointment in sufferers with psoriasis might also lower the plasma expression ranges of psoriasis-related cytokine expression. These findings point out that psoriasis will be thought to be a systemic illness, and Lindioil might considerably lower the Th17 cell inhabitants or related pathways. As well as, sufferers who achieved PASI 75 after 8 weeks of Lindioil remedy offered with decrease baseline plasma IL-17 expression; nonetheless, IL-17 was the one psoriasis-related cytokine discovered to be considerably diminished in sufferers with higher remedy response, making this unlikely to mirror an total discount in irritation standing among the many good-responder inhabitants. Nevertheless, sufferers with a poor response to Lindioil might require mixture remedies utilizing different Medicines (eg, conventional immunosuppressants or anti-IL-23/IL-12 biologic brokers) or therapeutic approaches (phototherapy) to enhance remedy response and suppress psoriasis-related cytokine expression.
One of many limitations of this examine was the variety of circumstances recruited at two hospital facilities. Not all sufferers with psoriasis who have been handled throughout the trial examine interval agreed to the extraction of adequate blood samples for the efficiency of genetic analyses; nonetheless, all sufferers who obtained a genetic evaluation have been included in our cohort examine. We have been unable to exhibit any vital correlation between HLA-Cw allele standing and cytokine expression patterns amongst sufferers with psoriasis (information not proven), and solely 5 varieties of psoriasis-related cytokines have been investigated. Cytokine expression evaluation carried out utilizing pores and skin specimens obtained from psoriasis lesion may be extra strongly correlated with illness severity and remedy response than the cytokine expression sample in plasma. Massive-scale research stay vital to totally consider the affect of HLA-Cw allele standing and cytokine expression patterns on the response to Lindioil remedy.
Conclusion
In conclusion, HLA-Cw*01:02-negative and HLA-Cw*06:02-positive standing and decrease plasma IL-17 ranges have been correlated with Lindioil remedy response amongst psoriasis sufferers. Our examine supplies predictive markers for remedy response which can result in enhancements within the topical Lindioil remedy in sufferers with psoriasis.
Information Sharing Assertion
The datasets generated throughout and/or analysed throughout the present examine can be found from first writer, Yin-Ku Lin, on cheap request.
Acknowledgment
We thank Entire-Genome Analysis Core Laboratory of Human Ailments, Chang Gung Memorial Hospital, Keelung, Taiwan, for supporting the HLA management database on this examine.
Writer Contributions
All authors made substantial contributions to conception and design, acquisition of knowledge, or evaluation and interpretation of knowledge; took half in drafting the article or revising it critically for essential mental content material; agreed to undergo the present journal; gave last approval of the model to be revealed; and comply with be accountable for all points of the work.
Funding
This work was supported partly by grants from the Ministry of Science and Know-how, Taiwan (MOST 106-2314-B-182A-037-MY3, 107-2320-B-182A-002-MY3, 108-2622-B-182A-003-CC2, 108-2314-B-182A-104-MY3, 108-2320-B-182A-024-MY2, 108-2314-B-182A-006-MY3, and 109-2326-B-182A-001-, 110-2320-B-182A-014 -MY3) and Chang Gung Memorial Hospital (CLRPG3J0011-3, CMRPG3I0381-2, CORPG1J0011~3, CORPG3J0321-3, and CMRPG3K0561-2).
Disclosure
The authors declare no conflicts of curiosity for this work and that they haven’t any recognized competing monetary pursuits or private relationships that would have appeared to affect the work reported on this paper.
References
1. Perera GK, Di Meglio P, Nestle FO. Psoriasis. Annu Rev Pathol. 2012;7:385–422. doi:10.1146/annurev-pathol-011811-132448
2. Griffiths CE, Barker JN. Pathogenesis and scientific options of psoriasis. Lancet. 2007;370(9583):263–271. doi:10.1016/s0140-6736(07)61128-3
3. Fowler JF, Duh MS, Rovba L, et al. The impression of psoriasis on well being care prices and affected person work loss. J Am Acad Dermatol. 2008;59(5):772–780. doi:10.1016/j.jaad.2008.06.043
4. Tadros A, Vergou T, Stratigos AJ, et al. Psoriasis: is it the tip of the iceberg for the standard of lifetime of sufferers and their households? J Eur Acad Dermatol Venereol. 2011;25(11):1282–1287. doi:10.1111/j.1468-3083.2010.03965.x
5. Liu Y, Helms C, Liao W, et al. A genome-wide affiliation examine of psoriasis and psoriatic arthritis identifies new illness loci. PLoS Genet. 2008;4(3):e1000041. doi:10.1371/journal.pgen.1000041
6. Borroni RG, Costanzo A. HLA-C*06 and psoriasis: susceptibility, phenotype, course and response to remedy. Br J Dermatol. 2018;178(4):825. doi:10.1111/bjd.16412
7. West J, Ogston S, Berg J, et al. HLA-Cw6-positive sufferers with psoriasis present improved response to methotrexate remedy. Clin Exp Dermatol. 2017;42(6):651–655. doi:10.1111/ced.13100
8. Chiu HY, Wang TS, Chan CC, Cheng YP, Lin SJ, Tsai TF. Human leucocyte antigen-Cw6 as a predictor for scientific response to ustekinumab, an interleukin-12/23 blocker, in Chinese language sufferers with psoriasis: a retrospective evaluation. Br J Dermatol. 2014;171(5):1181–1188. doi:10.1111/bjd.13056
9. Lin YK, Yen HR, Wong WR, Yang SH, Pang JH. Profitable remedy of pediatric psoriasis with Indigo naturalis composite ointment. Pediatr Dermatol. 2006;23(5):507–510. doi:10.1111/j.1525-1470.2006.00295.x
10. Lin YK, See LC, Huang YH, et al. Comparability of refined and crude indigo naturalis ointment in treating psoriasis: randomized, observer-blind, managed, intrapatient trial. Arch Dermatol. 2012;148(3):397–400. doi:10.1001/archdermatol.2011.1091
11. Lin YK, See LC, Huang YH, Chi CC, Hui RC. Comparability of indirubin concentrations in indigo naturalis ointment for psoriasis remedy: a randomized, double-blind, dosage-controlled trial. Br J Dermatol. 2018;178(1):124–131. doi:10.1111/bjd.15894
12. Cheng HM, Kuo YZ, Chang CY, et al. The anti-TH17 polarization impact of Indigo naturalis and tryptanthrin by differentially inhibiting cytokine expression. J Ethnopharmacol. 2020;255:112760. doi:10.1016/j.jep.2020.112760
13. Lin YK, Wong WR, Chang YC, et al. The efficacy and security of topically utilized indigo naturalis ointment in sufferers with plaque-type psoriasis. Dermatology. 2007;214(2):155–161. doi:10.1159/000098576
14. Moon MJ, Lee SK, Lee JW, et al. Synthesis and structure-activity relationships of novel indirubin derivatives as potent anti-proliferative brokers with CDK2 inhibitory actions. Bioorg Med Chem. 2006;14(1):237–246. doi:10.1016/j.bmc.2005.08.008
15. Marko D, Schätzle S, Friedel A, et al. Inhibition of cyclin-dependent kinase 1 (CDK1) by indirubin derivatives in human tumour cells. Br J Most cancers. 2001;84(2):283–289. doi:10.1054/bjoc.2000.1546
16. Lin YK, Leu YL, Yang SH, Chen HW, Wang CT, Pang JH. Anti-psoriatic results of indigo naturalis on the proliferation and differentiation of keratinocytes with indirubin because the lively part. J Dermatol Sci. 2009;54(3):168–174. doi:10.1016/j.jdermsci.2009.02.007
17. Hsieh WL, Lin YK, Tsai CN, Wang TM, Chen TY, Pang JH. Indirubin, an appearing part of indigo naturalis, inhibits EGFR activation and EGF-induced CDC25B gene expression in epidermal keratinocytes. J Dermatol Sci. 2012;67(2):140–146. doi:10.1016/j.jdermsci.2012.05.008
18. Hoessel R, Leclerc S, Endicott JA, et al. Indirubin, the lively constituent of a Chinese language antileukaemia medication, inhibits cyclin-dependent kinases. Nat Cell Biol. 1999;1(1):60–67. doi:10.1038/9035
19. Lin YK, Chen HW, Leu YL, et al. Indigo naturalis upregulates claudin-1 expression in human keratinocytes and psoriatic lesions. J Ethnopharmacol. 2013;145(2):614–620. doi:10.1016/j.jep.2012.11.044
20. Cheng HM, Wu YC, Wang Q, et al. Scientific efficacy and IL-17 focusing on mechanism of Indigo naturalis as a topical agent in average psoriasis. BMC Complement Altern Med. 2017;17(1):439. doi:10.1186/s12906-017-1947-1
21. Bungsu I, Kifli N, Ahmad SR, Ghani H, Cunningham AC. Natural Crops: the Function of AhR in Mediating Immunomodulation. Mini Rev. 2021;12(2491). doi:10.3389/fimmu.2021.697663
22. Peter Guengerich F, Martin MV, McCormick WA, Nguyen LP, Glover E, Bradfield CA. Aryl hydrocarbon receptor response to indigoids in vitro and in vivo. Arch Biochem Biophys. 2004;423(2):309–316. doi:10.1016/j.abb.2004.01.002
23. Chang HN, Pang JH, Yang SH, et al. Inhibitory impact of indigo naturalis on tumor necrosis factor-α-induced vascular cell adhesion molecule-1 expression in human umbilical vein endothelial cells. Molecules. 2010;15(9):6423–6435. doi:10.3390/molecules15096423
24. Chen L. Tsai TF. HLA-Cw6 and psoriasis. Br J Dermatol. 2018;178(4):854–862. doi:10.1111/bjd.16083
25. Indhumathi S, Rajappa M, Chandrashekar L, Ananthanarayanan PH, Thappa DM, Negi VS. Pharmacogenetic markers to foretell the scientific response to methotrexate in south Indian Tamil sufferers with psoriasis. Eur J Clin Pharmacol. 2017;73(8):965–971. doi:10.1007/s00228-017-2255-x
26. Papini M, Cusano F, Romanelli M, et al. Secukinumab exhibits excessive efficacy no matter HLA-Cw6 standing in sufferers with moderate-to-severe plaque-type psoriasis: outcomes from extension part of the SUPREME examine. Br J Dermatol. 2019;181(2):413–414. doi:10.1111/bjd.18013
27. Gallo E, Cabaleiro T, Román M, et al. The connection between tumour necrosis issue (TNF)-α promoter and IL12B/IL-23R genes polymorphisms and the efficacy of anti-TNF-α remedy in psoriasis: a case-control examine. Br J Dermatol. 2013;169(4):819–829. doi:10.1111/bjd.12425
28. Dand N, Duckworth M, Baudry D, et al. HLA-C*06:02 genotype is a predictive biomarker of biologic remedy response in psoriasis. J Allergy Clin Immunol. 2019;143(6):2120–2130. doi:10.1016/j.jaci.2018.11.038
29. Cai M, Huang H, Ran D, et al. HLA-C*01:02 and HLA-A*02:07 confer danger particular for psoriatic sufferers in Southern China. J Make investments Dermatol. 2019;139(9):2045–2048.e4. doi:10.1016/j.jid.2019.02.027
30. Chiu HY, Huang PY, Jee SH, et al. HLA polymorphism amongst Chinese language sufferers with continual plaque psoriasis: subgroup evaluation. Br J Dermatol. 2012;166(2):288–297. doi:10.1111/j.1365-2133.2011.10688.x
31. Nakagawa H, Asahina A, Akazaki S, et al. Affiliation of Cw11 in Japanese sufferers with psoriasis vulgaris. Tissue Antigens. 1990;36(5):241–242. doi:10.1111/j.1399-0039.1990.tb01835.x
32. Szczerkowska Dobosz A, Rebała Ok, Szczerkowska Z, Nedoszytko B. HLA-C locus alleles distribution in sufferers from northern Poland with psoriatic arthritis–preliminary report. Int J Immunogenet. 2005;32(6):389–391. doi:10.1111/j.1744-313X.2005.00543.x
33. Zhang XJ, Zhang AP, Yang S, et al. Affiliation of HLA class I alleles with psoriasis vulgaris in southeastern Chinese language Hans. J Dermatol Sci. 2003;33(1):1–6. doi:10.1016/s0923-1811(0300157-9)
34. Huang YW. Tsai TF. HLA-Cw1 and Psoriasis. Am J Clin Dermatol. 2021;22(3):339–347. doi:10.1007/s40257-020-00585-1
35. Edson-Heredia E, Sterling KL, Alatorre CI, et al. Heterogeneity of response to biologic remedy: perspective for psoriasis. J Make investments Dermatol. 2014;134(1):18–23. doi:10.1038/jid.2013.326